Arcturus Therapeutics Holdings Stock Market Value
| ARCT Stock | USD 17.51 0.58 3.43% |
| Symbol | Arcturus |
Arcturus Therapeutics Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Arcturus Therapeutics. If investors know Arcturus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Arcturus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.33) | Revenue Per Share 5.955 | Quarterly Revenue Growth (0.08) | Return On Assets (0.12) | Return On Equity (0.23) |
The market value of Arcturus Therapeutics is measured differently than its book value, which is the value of Arcturus that is recorded on the company's balance sheet. Investors also form their own opinion of Arcturus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Arcturus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Arcturus Therapeutics' market value can be influenced by many factors that don't directly affect Arcturus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Arcturus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Arcturus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Arcturus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Arcturus Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Arcturus Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Arcturus Therapeutics.
| 09/29/2024 |
| 11/28/2024 |
If you would invest 0.00 in Arcturus Therapeutics on September 29, 2024 and sell it all today you would earn a total of 0.00 from holding Arcturus Therapeutics Holdings or generate 0.0% return on investment in Arcturus Therapeutics over 60 days. Arcturus Therapeutics is related to or competes with 89bio, Madrigal Pharmaceuticals, Pliant Therapeutics, Arcellx, Stoke Therapeutics, Intellia Therapeutics, and Beam Therapeutics. Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, an... More
Arcturus Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Arcturus Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Arcturus Therapeutics Holdings upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.07) | |||
| Maximum Drawdown | 21.47 | |||
| Value At Risk | (5.87) | |||
| Potential Upside | 5.57 |
Arcturus Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Arcturus Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Arcturus Therapeutics' standard deviation. In reality, there are many statistical measures that can use Arcturus Therapeutics historical prices to predict the future Arcturus Therapeutics' volatility.| Risk Adjusted Performance | (0.02) | |||
| Jensen Alpha | (0.33) | |||
| Total Risk Alpha | (0.79) | |||
| Treynor Ratio | (0.13) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Arcturus Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Arcturus Therapeutics Backtested Returns
Arcturus Therapeutics secures Sharpe Ratio (or Efficiency) of -0.0487, which signifies that the company had a -0.0487% return per unit of standard deviation over the last 3 months. Arcturus Therapeutics Holdings exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Arcturus Therapeutics' risk adjusted performance of (0.02), and Mean Deviation of 3.15 to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 1.33, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Arcturus Therapeutics will likely underperform. At this point, Arcturus Therapeutics has a negative expected return of -0.2%. Please make sure to confirm Arcturus Therapeutics' potential upside, and the relationship between the jensen alpha and rate of daily change , to decide if Arcturus Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.28 |
Poor predictability
Arcturus Therapeutics Holdings has poor predictability. Overlapping area represents the amount of predictability between Arcturus Therapeutics time series from 29th of September 2024 to 29th of October 2024 and 29th of October 2024 to 28th of November 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Arcturus Therapeutics price movement. The serial correlation of 0.28 indicates that nearly 28.0% of current Arcturus Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.28 | |
| Spearman Rank Test | 0.46 | |
| Residual Average | 0.0 | |
| Price Variance | 1.29 |
Arcturus Therapeutics lagged returns against current returns
Autocorrelation, which is Arcturus Therapeutics stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Arcturus Therapeutics' stock expected returns. We can calculate the autocorrelation of Arcturus Therapeutics returns to help us make a trade decision. For example, suppose you find that Arcturus Therapeutics has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Arcturus Therapeutics regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Arcturus Therapeutics stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Arcturus Therapeutics stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Arcturus Therapeutics stock over time.
Current vs Lagged Prices |
| Timeline |
Arcturus Therapeutics Lagged Returns
When evaluating Arcturus Therapeutics' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Arcturus Therapeutics stock have on its future price. Arcturus Therapeutics autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Arcturus Therapeutics autocorrelation shows the relationship between Arcturus Therapeutics stock current value and its past values and can show if there is a momentum factor associated with investing in Arcturus Therapeutics Holdings.
Regressed Prices |
| Timeline |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Arcturus Stock Analysis
When running Arcturus Therapeutics' price analysis, check to measure Arcturus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcturus Therapeutics is operating at the current time. Most of Arcturus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Arcturus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcturus Therapeutics' price. Additionally, you may evaluate how the addition of Arcturus Therapeutics to your portfolios can decrease your overall portfolio volatility.